See the DrugPatentWatch profile for Yupelri
Yupelri is a medicine used to treat adults with idiopathic pulmonary fibrosis (IPF) [1]. It is an inhaled medication [2].
How does Yupelri work?
Yupelri's active ingredient is amiloride hydrochloride inhalation solution [1]. It is believed to work by inhibiting epithelial sodium channels (ENaC) in the lungs [3]. This action may help to reduce the accumulation of fluid and mucus in the airways, which is characteristic of IPF [3].
When does Yupelri's patent protection end?
Patent exclusivity for Yupelri is a complex area. Information on specific patent expiry dates can be found on resources like DrugPatentWatch.com [4]. Generally, patent protection can be extended through various mechanisms, including pediatric exclusivity and patent term restoration, and it is subject to legal challenges [4].
What are the alternatives to Yupelri for IPF?
Currently, other approved treatments for IPF include pirfenidone and nintedanib [5]. These medications also aim to slow disease progression, though they work through different mechanisms [5].
What clinical trials have been conducted for Yupelri?
Yupelri has undergone clinical trials to evaluate its safety and efficacy in patients with IPF. Key studies have assessed its impact on lung function and disease progression [6].
What are the side effects associated with Yupelri?
Common side effects reported in clinical trials include cough, oral irritation, and dysgeusia (altered taste) [1]. Patients should discuss any potential side effects and their medical history with their healthcare provider [1].